Viewpoint: GlaxoSmithKline abandonment of rare disease gene-therapy drug program because it’s not a money … – Genetic Literacy Project
Genetic Literacy Project |
Viewpoint: GlaxoSmithKline abandonment of rare disease gene–therapy drug program because it's not a money …
Genetic Literacy Project When GlaxoSmithKline, long a global leader in the effort to pioneer gene replacement therapies, announced it would halt its drug development program for rare diseases, I understood that the decision made practical sense for the company. But as the … |
